Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 3/20 | 0.51 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.49 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.49 |
| ▸ | GLP1R | P43220 | 9/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
| ▸ | CALCR | P30988 | 4/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | NMBR | P28336 | 1/20 | 0.47 |
| ▸ | GRPR | P30550 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30996216 | 1.00 | KISS1R (0.51) | KISS1RCRHR1CRHR2GLP1ROPRD1 | |
| SCHEMBL31450045 | 1.00 | KISS1R (0.51) | KISS1RCRHR1CRHR2GLP1ROPRD1 | |
| SCHEMBL30030154 | 0.96 | OPRD1 (0.52) | KISS1RGLP1ROPRD1NMBRGRPR | |
| SCHEMBL30874967 | 0.96 | GLP1R (0.52) | KISS1RCRHR1CRHR2GLP1ROPRD1 | |
| SCHEMBL30874946 | 0.96 | GLP1R (0.52) | KISS1RCRHR1CRHR2GLP1ROPRD1 | |
| SCHEMBL29649710 | 0.95 | GLP1R (0.50) | KISS1RCRHR1CRHR2GLP1ROPRD1 | |
| SCHEMBL30874972 | 0.92 | OPRD1 (0.53) | GLP1ROPRD1 | |
| SCHEMBL30662034 | 0.91 | GLP1R (0.53) | GLP1ROPRD1CALCRF2 | |
| SCHEMBL29836503 | 0.86 | GLP1R (0.55) | CRHR1CRHR2GLP1RCALCRF2 | |
| SCHEMBL30168721 | 0.86 | F2 (0.57) | CRHR1CRHR2GLP1RCALCRF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099554-A1 | COMPOSITIONS AND METHODS OF FAS INHIBITION | ONL THERAPEUTICS INC (US) | 2025-03-27 | — | — | US | disclosed |
| EP-4370208-A2 | METHODS AND COMPOSITIONS FOR IMPROVING VISUAL FUNCTION IN OCULAR DISEASES AND DISORDERS | ONL Therapeutics, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| US-20240156898-A1 | METHODS AND COMPOSITIONS FOR TREATING OCULAR DISORDERS AND DISEASES | ONL THERAPEUTICS, INC. | 2024-05-16 | — | — | US | disclosed |
| EP-4355349-A1 | METHODS AND COMPOSITIONS FOR TREATING OCULAR DISORDERS AND DISEASES | ONL Therapeutics, Inc. (US) | 2024-04-24 | — | — | EP | disclosed |
| WO-2023287794-A2 | METHODS AND COMPOSITIONS FOR IMPROVING VISUAL FUNCTION IN OCULAR DISEASES AND DISORDERS | ONL THERAPEUTICS, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| WO-2022266127-A1 | METHODS AND COMPOSITIONS FOR TREATING OCULAR DISORDERS AND DISEASES | ONL THERAPEUTICS, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240156898-A1 | METHODS AND COMPOSITIONS FOR TREATING OCULAR DISORDERS AND DISEASES | UACA, ASAH2, NFKBIA | KISS1R 4789/4885CRHR1 2283/4885CRHR2 2273/4885 |
| US-20250099554-A1 | COMPOSITIONS AND METHODS OF FAS INHIBITION | CFB, BAX, FASN | KISS1R 4883/4885CRHR1 4428/4885CRHR2 4419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.